HER2+ Gastric Cancer Market Set for Transformative Growth Through 2034, Driven by Targeted Therapies and Rising Disease Burden | DelveInsight

HER2+ Gastric Cancer is an aggressive subtype of gastric and gastroesophageal junction cancers, defined by the overexpression of the HER2 (human epidermal growth factor receptor 2) protein. Affecting around 15-20% of gastric cancer patients, this form is associated with rapid progression and poor outcomes if left untreated. However, advancements in HER2+ Gastric Cancer treatment, particularly targeted therapies, have significantly improved survival in recent years.

DelveInsight's latest report, "HER2+ Gastric Cancer - Market Insight, Epidemiology, and Market Forecast - 2034," offers a detailed examination of the evolving landscape, covering key markets such as the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. The report delves into HER2+ Gastric Cancer epidemiology, disease burden, and patient segmentation by age, gender, and biomarker status, while also highlighting trends in diagnosis, symptoms, and therapeutic uptake.

While HER2-targeted agents like trastuzumab and trastuzumab deruxtecan (ENHERTU) have redefined the standard of care, resistance, tumor heterogeneity, and underutilization of biomarker testing continue to pose challenges. The development pipeline remains robust, with several HER2+ Gastric Cancer drugs in late-stage trials, including antibody-drug conjugates, bispecifics, and immune-oncology combinations.

With growing disease awareness, increasing biomarker-driven diagnoses, and the anticipated launch of novel HER2+ Gastric Cancer therapies, the market is set for meaningful expansion through 2034. This offers significant opportunities for pharmaceutical innovators and healthcare providers to improve outcomes in a historically underserved patient population.

Request a sample and uncover the latest breakthroughs shaping the HER2+ gastric cancer market landscape and future outlook @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Some of the key insights of the HER2+ Gastric Cancer Market Report:
• In 2024, the HER2+ gastric cancer market in the 7MM reached ~USD 700 million, with growth expected by 2034.
• The U.S. led the market with ~USD 300 million in 2024, projected to rise further.
• The 7MM reported ~211K incident gastric cancer (incl. GEJ) cases in 2024, expected to increase.
• Japan accounted for ~60% of HER2+ cases, while the EU4 and the UK made up ~25%.
• In the U.S., males represented 66% of gastric cancer cases in 2024.
• ENHERTU, effective in 2L treatment, is under evaluation for 1L HER2+ gastric cancer.
• In June 2025, Guardant Health, Inc. (Nasdaq: GH) announced that its Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the FDA. The methylation-based blood test is designed to screen for multiple cancers, including bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic, in adults aged 45+ at average risk.
• In March 2025, the FDA granted traditional approval for frontline pembrolizumab (KEYTRUDA) in combination with trastuzumab and chemotherapy (fluoropyrimidine- and platinum-based) for adults with locally advanced, unresectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) of at least 1 (CPS ≥1).
• In February 2025, AstraZeneca anticipates a data readout from the Phase Ib/II (NCT04379596, DESTINY-Gastric03) trial, which is focused on treating metastatic or unresectable HER2+ gastric cancer, GEJ, and GEA, in 2026.
• In February 2025, AstraZeneca expects the first patient dosing of ENHERTU (NCT06731478, DESTINY-Gastric05) for HER2+ first-line locally advanced or metastatic gastric cancer or GEJ adenocarcinoma to begin in Q1 2025, with data anticipated to be available after 2026.
• In the January 2025 presentation, Jazz Pharmaceuticals anticipates the potential approval and launch of zanidatamab as a first-line treatment for GEA in 2026. Additionally, the company is also looking forward to expanding its market strategy for zanidatamab in 2026.
• AstraZeneca anticipates data from the DESTINY-Gastric04 (NCT04704934) trial, which is focused on treating HER2+ gastric cancer or GEJ adenocarcinoma patients who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy, to be available in H2 2025.
• In January 2025, ALX Oncology presented positive updated data from the ASPEN-06 Phase II clinical trial at the 2025 ASCO Gastrointestinal Cancers Symposium, demonstrating that the company's investigational CD47-blocker, evorpacept, produces a durable clinical response and exhibits a well-tolerated safety profile in patients with previously treated HER2+ advanced gastric cancer or GEJ cancer.
• Emerging therapies for HER2+ gastric cancer include ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others.
• Key companies involved in the treatment of HER2+ gastric cancer include Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others.

To know in detail about the HER2+ gastric cancer market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

HER2+ Gastric Cancer Overview
HER2+ Gastric Cancer is a biologically distinct subtype of gastric and gastroesophageal junction (GEJ) cancers characterized by the overexpression or amplification of the human epidermal growth factor receptor 2 (HER2). HER2 is a transmembrane tyrosine kinase receptor involved in cell growth and differentiation. Overexpression of HER2 in gastric cancer is observed in approximately 15-20% of cases and is more common in intestinal-type and GEJ tumors.

This subtype is typically more aggressive, with a poorer prognosis compared to HER2-negative forms. However, the identification of HER2 as a therapeutic target has transformed treatment strategies. The approval of trastuzumab in combination with chemotherapy marked a turning point, and more recently, trastuzumab deruxtecan (Enhertu) has shown significant efficacy in previously treated patients.

Accurate HER2 testing (IHC and FISH) is critical for guiding treatment decisions. Despite therapeutic advancements, issues such as primary resistance, acquired resistance, and tumor heterogeneity continue to limit long-term outcomes, underscoring the need for continued innovation and combination approaches in HER2+ Gastric Cancer treatment.

Get a free sample for the HER2+ gastric cancer market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

HER2+ Gastric Cancer Epidemiology
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

HER2+ Gastric Cancer Epidemiology Segmentation:
The HER2+ gastric cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into:
• Total incident cases of gastric cancer (including GEJ)
• Gender-specific cases of gastric cancer (including GEJ)
• Stage-specific cases of gastric cancer (including GEJ)
• Total incident cases of HER2+ gastric cancer (including GEJ)
• Total incident cases of advanced HER2+ gastric cancer (including GEJ)

HER2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities
The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for HER2+ Gastric Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the HER2+ Gastric Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for HER2+ Gastric Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of HER2+ Gastric Cancer therapeutics.

Explore how emerging HER2+ gastric cancer therapies are aligning with evolving patient populations @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

HER2+ Gastric Cancer Market Outlook
The HER2+ Gastric Cancer treatment landscape has seen a major transformation with the shift from conventional chemotherapy to targeted and immune-based therapies. The approval of HERCEPTIN in the first-line setting, followed by KEYTRUDA in combination with trastuzumab and chemotherapy, and ENHERTU as a second-line option, has significantly improved outcomes for patients with HER2+ gastric and GEJ adenocarcinoma. Previously, second-line treatment was limited to chemotherapies like paclitaxel or irinotecan, but ENHERTU has now become the preferred option in this space.

Looking ahead, the HER2+ Gastric Cancer market is poised for steady growth through 2034, driven by increased biomarker testing, better patient stratification, and ongoing innovation in HER2+ gastric cancer drugs. Promising pipeline candidates such as Zanidatamab, Rilvegostomig, Evorpacept, and HLX22 are being developed to address current treatment gaps, including resistance and tumor heterogeneity. These upcoming HER2+ gastric cancer therapies, ranging from antibody-drug conjugates to bispecifics and immuno-oncology combinations, are expected to elevate the standard of care further and expand therapeutic options for patients.

HER2+ Gastric Cancer Market Drivers
• The approval and adoption of targeted agents like trastuzumab, trastuzumab deruxtecan (ENHERTU), and immune-based combinations have significantly improved survival outcomes, reshaping the treatment landscape and driving market growth.
• Increased HER2 testing and biomarker-driven patient selection enable early identification of eligible patients, improving treatment precision and expanding the eligible treatment population.

HER2+ Gastric Cancer Market Barriers
• Primary and acquired resistance to HER2-targeted therapies, along with variability in HER2 expression across tumor sites, limit long-term treatment efficacy and patient outcomes.
• Despite recent approvals, there is still a lack of standardized third-line or beyond therapies, creating a treatment gap and unmet need for patients progressing on available HER2+ gastric cancer drugs.

Scope of the HER2+ Gastric Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key HER2+ Gastric Cancer Companies: Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, LintonPharm, Qilu Pharmaceutical Co., Shanghai Henlius Biotech, Bayer, Bristol-Myers Squibb, Ono Pharmaceutical, Jiangsu HengRui Medicine, Seagen, MacroGenics, Zai Lab, Merck Sharp & Dohme Corp., Eisai Inc., Merus N.V., OncXerna Therapeutics, Innovent Biologics, and others.
• Key HER2+ Gastric Cancer Therapies: ZIIHERA (zanidatamab), Rilvegostomig, HLX22 (AC101), Evorpacept (ALX148), TUKYSA (tucatinib), BAY2927088, AB-201 (GCC2003, HER2 CAR-NK), A166 (Trastuzumab botidotin), MRG002, AIDIXI (disitamab vedotin), BAY2701439, ELVN-002, ARX788, XMT-2056, BL-M07D1, and others.
• HER2+ Gastric Cancer Therapeutic Assessment: HER2+ Gastric Cancer currently marketed, and HER2+ Gastric Cancer emerging therapies.
• HER2+ Gastric Cancer Market Dynamics: HER2+ Gastric Cancer market drivers and HER2+ Gastric Cancer market barriers.
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies.
• HER2+ Gastric Cancer Unmet Needs, KOL's views, Analyst's views, HER2+ Gastric Cancer Market Access and Reimbursement.

To learn more about HER2+ gastric cancer companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. HER2+ Gastric Cancer Market Report Introduction
2. Executive Summary for HER2+ Gastric Cancer
3. SWOT analysis of HER2+ Gastric Cancer
4. HER2+ Gastric Cancer Patient Share (%) Overview at a Glance
5. HER2+ Gastric Cancer Market Overview at a Glance
6. HER2+ Gastric Cancer Disease Background and Overview
7. HER2+ Gastric Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of HER2+ Gastric Cancer
9. HER2+ Gastric Cancer Current Treatment and Medical Practices
10. HER2+ Gastric Cancer Unmet Needs
11. HER2+ Gastric Cancer Emerging Therapies
12. HER2+ Gastric Cancer Market Outlook
13. Country-Wise HER2+ Gastric Cancer Market Analysis (2020-2034)
14. HER2+ Gastric Cancer Market Access and Reimbursement of Therapies
15. HER2+ Gastric Cancer Market Drivers
16. HER2+ Gastric Cancer Market Barriers
17. HER2+ Gastric Cancer Appendix
18. HER2+ Gastric Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.